Credit: Vanderbilt University Medical CenterBackground on Prostate Cancer ScreeningProstate cancer is the most typical cancer and the 2nd leading cause of cancer death among males in the U.S. For patients with a raised PSA, there is a terrific requirement for a second-line test to better recognize which males genuinely require a biopsy and which do not.Development of MPS2Because some low-grade, prostate cancers do not require treatment and can be securely kept track of with an approach called active surveillance, the MPS2 test was developed to discover more particularly the higher-grade, “clinically substantial” cancers in requirement of early detection and treatment.To do this, the research study team analyzed prostate growths from throughout the U.S. to determine unique genes more frequently identified in the presence of substantial cancers. Because prostate cancer is more common among African American men, the research group is presently pursuing additional analyses in more racially varied populations.For more on this research, see New Urine-Based Test Detects High-Grade Prostate Cancer.Reference: “Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer” by Jeffrey J. Tosoian, Yuping Zhang, Lanbo Xiao, Cassie Xie, Nathan L. Samora, Yashar S. Niknafs, Zoey Chopra, Javed Siddiqui, Heng Zheng, Grace Herron, Neil Vaishampayan, Hunter S. Robinson, Kumaran Arivoli, Bruce J. Trock, Ashley E. Ross, Todd M. Morgan, Ganesh S. Palapattu, Simpa S. Salami, Lakshmi P. Kunju, Scott A. Tomlins, Lori J. Sokoll, Daniel W. Chan, Sudhir Srivastava, Ziding Feng, Martin G. Sanda, Yingye Zheng, John T. Wei, Arul M. Chinnaiyan, EDRN-PCA3 Study Group, Ian M. Thompson, Mohamed Bidair, Adam Kibel, Daniel W. Lin, Yair Lotan, Alan Partin, Samir Taneja, David H. Howard, Meredith M. Regan, Jack Groskopf, Jonathan Chipman, Dattatraya H. Patil, Douglas S. Scherr, Jacob Kagan, Jing Fan, Aron Y. Joon, Leonidas E. Bantis and Mark A. Rubin, 18 April 2024, JAMA Oncology.DOI: 10.1001/ jamaoncol.2024.0455 Tosoian is co-first author with Yuping Zhang, PhD, and Lanbo Xiao, PhD, teachers at the University of Michigan, where Tosoian and Arul Chinnaiyan, MD, PhD, initiated the research study.
Credit: Vanderbilt University Medical CenterBackground on Prostate Cancer ScreeningProstate cancer is the most common cancer and the 2nd leading cause of cancer death amongst guys in the U.S. For clients with an elevated PSA, there is an excellent need for a second-line test to better identify which males really require a biopsy and which do not.Development of MPS2Because some low-grade, prostate cancers do not require treatment and can be securely kept an eye on with a technique described active security, the MPS2 test was developed to spot more particularly the higher-grade, “medically significant” cancers in requirement of early detection and treatment.To do this, the research study team evaluated prostate tumors from across the U.S. to recognize novel genes more frequently discovered in the existence of substantial cancers. Since prostate cancer is more prevalent among African American males, the research study team is presently pursuing more analyses in more racially varied populations.For more on this research, see New Urine-Based Test Detects High-Grade Prostate Cancer.Reference: “Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer” by Jeffrey J. Tosoian, Yuping Zhang, Lanbo Xiao, Cassie Xie, Nathan L. Samora, Yashar S. Niknafs, Zoey Chopra, Javed Siddiqui, Heng Zheng, Grace Herron, Neil Vaishampayan, Hunter S. Robinson, Kumaran Arivoli, Bruce J. Trock, Ashley E. Ross, Todd M. Morgan, Ganesh S. Palapattu, Simpa S. Salami, Lakshmi P. Kunju, Scott A. Tomlins, Lori J. Sokoll, Daniel W. Chan, Sudhir Srivastava, Ziding Feng, Martin G. Sanda, Yingye Zheng, John T. Wei, Arul M. Chinnaiyan, EDRN-PCA3 Study Group, Ian M. Thompson, Mohamed Bidair, Adam Kibel, Daniel W. Lin, Yair Lotan, Alan Partin, Samir Taneja, David H. Howard, Meredith M. Regan, Jack Groskopf, Jonathan Chipman, Dattatraya H. Patil, Douglas S. Scherr, Jacob Kagan, Jing Fan, Aron Y. Joon, Leonidas E. Bantis and Mark A. Rubin, 18 April 2024, JAMA Oncology.DOI: 10.1001/ jamaoncol.2024.0455 Tosoian is co-first author with Yuping Zhang, PhD, and Lanbo Xiao, PhD, professors at the University of Michigan, where Tosoian and Arul Chinnaiyan, MD, PhD, started the research study.